Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 2

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 -                  Net Loss $(1,225,912) $(2,229,153) $(2,262,242) $(5,004,853)                 Net loss per share – basic and diluted $(1.71) $(0.08) $(3.55) $(0.26)                 Weighted average common shares – basic and diluted  717,107   15,590   637,362   10,857 

The accompanying notes are an integral part of these financial statements.

 4Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

Six Months Ended June 30,2024  Series A Convertible  Series B Convertible       Additional      Total    Preferred Stock  Preferred Stock  Common stock  Paid in   Stock  Accumulated  Stockholders'    Shares   Amount   Shares   Amount   Shares   Amount   Capital   Payable  Deficit   Equity Balance as of December 31, 2023   141,397  $1   -  $-   5,937  $ 1-  $97,583,906  $5,233  $(91,930,152) $5,658,989 Preferred stock conversion to common stock  (123,909)  -1   -   -   5   -   1   -   -   - Common stock issued for cash  -   -   -   -   3,671   -   1,148,470   -   -   1,148,470 Common stock issued for warrant exercise                  25,408   2   5,366,678           5,366,680 Common stock issued for cashless warrant exercise                  6,327   -   1,320,568           1,320,568 Fair value of vested common stock  -   -   -   -   46   -   80,000   -   -   80,000 Fair value of vested stock options